0

<< Emergency Department Management Of Calcium-Channel Blocker, Beta Blocker, And Digoxin Toxicity

References

TOC Will Appear Here

References

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study will be included in bold type following the reference, where available. In addition, the most informative references cited in this paper, as determined by the authors, will be noted by an asterisk (*) next to the number of the reference.

  1. National Center for Health Statistics. Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: Centers for Disease Control and Prevention; 2013. Available at: http://www.cdc.gov/nchs/data/hus/hus12. pdf. Accessed October 15, 2013. (Government statistical report)
  2. U.S. Bureau of the Census. National Hospital Ambulatory Medical Care Survey: 2010 Emergency Department Summary Tables. Durham, NC: U.S. Bureau of the Census; 2010. Available at: http://www.cdc.gov/nchs/data/ahcd/ nhamcs_emergency/2010_ed_web_tables.pdf. Accessed October 15, 2013. (Census data report)
  3. Bronstein AC, Spyker DA, Cantilena LR, Jr., et al. 2011 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012;50(10):911-1164. (Database analysis)
  4. Aarnoudse AL, Dieleman JP, Stricker BH. Age- and genderspecific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30(5):431-436. (Population based cohort study; 1286 patients)
  5. Bhatia SJ. Digitalis toxicity--turning over a new leaf? West J Med. 1986;145(1):74-82. (Review)
  6. Haynes K, Heitjan D, Kanetsky P, et al. Declining public health burden of digoxin toxicity from 1991 to 2004. Clin Pharmacol Ther. 2008;84(1):90-94. (Survey of United States and United Kingdom database information)
  7. Deters M, Bergmann I, Enden G, et al. Calcium channel antagonist exposures reported to the Poisons Information Center Erfurt. Eur J Intern Med. 2011;22(6):616-620. (Analysis of reported poison exposures in Germany; 727 cases)
  8. DeWitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev. 2004;23(4):223-238. (Review)
  9. Ferrari R. Major differences among the three classes of calcium antagonists. Eur Heart J. 1997;18 Suppl A:A56-A70. (Comparative analysis of clinical trials)
  10. Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med. 1995;13(4):444-450. (Case report; 1 patient)
  11. Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann Intern Med. 2004;140(8):W31. (Case report; 1 patient)
  12. Reith DM, Dawson AH, Epid D, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34(3):273-278. (Prospective study; 60 patients)
  13. * Love JN, Howell JM, Litovitz TL, et al. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38(3):275-281. (Prospective cohort study; 280 exposures)
  14. Henry JA, Cassidy SL. Membrane stabilising activity: a ma jor cause of fatal poisoning. Lancet. 1986;1(8495):1414-1417. (Review)
  15. Weinstein RS. Recognition and management of poisoning with beta-adrenergic blocking agents. Ann Emerg Med. 1984;13(12):1123-1131. (Review)
  16. Fisch C. William Withering: An account of the foxglove and some of its medical uses 1785-1985. J Am Coll Cardiol. 1985;5(5 Suppl A):1A-2A. (Historical account)
  17. Katzung B. Drugs used in heart failure. In: Basic and Clinical Pharmacology. Katzung B, Masters S, eds. 12th ed. New York:McGraw-Hill; 2012:211-226. (Textbook)
  18. Kockova R, Skvaril J, Cernohous M, et al. Five-year, twocenter retrospective analysis of patients with toxic digoxin serum concentration. Int J Cardiol. 2011;146(3):447-448. (Retrospective analysis)
  19. Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6(2):77-86. (Review)
  20. Kanji S, MacLean RD. Cardiac glycoside toxicity: more than 200 years and counting. Crit Care Clin. 2012;28(4):527-535. (Review)
  21. Vivo RP, Krim SR, Perez J, et al. Digoxin: current use and approach to toxicity. Am J Med Sci. 2008;336(5):423-428. (Review)
  22. Hack JB. Cardioactive Steroids. In: Nelson LS, Lewin NA, Howland MA, et al, eds. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011:936-945. (Textbook)
  23. Rodin SM, Johnson BF. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 1988;15(4):227-244. (Review)
  24. Haynes K, Hennessy S, Localio AR, et al. Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiol Drug Saf. 2009;18(1):28-35. (Prospective cohort study; 2030 patients)
  25. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86(4):383-386. (15-year population-based nested case-control study)
  26. Lee CY, Marcotte F, Giraldeau G, et al. Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature. Can J Cardiol. 2011;27(6):870 e815-e876. (Case presentation and review)
  27. Xu H, Rashkow A. Clarithromycin-induced digoxin toxicity: a case report and a review of the literature. Conn Med. 2001;65(9):527-529. (Case report)
  28. Chan AL, Wang MT, Su CY, et al. Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study. Eur J Clin Pharmacol. 2009;65(12):1237-1243. (Retrospective study; 595 cases and 27,020 matched controls)
  29. Kunz A, Marty H, Nohl F, et al. Mixed intoxication with Aconitum nappellans (monkshood) and Digitalis grandiflora (large yellow foxglove). Med Sci Monit. 2010;16(8):CS103- CS105. (Case report; 1 patient)
  30. Maffe S, Cucchi L, Zenone F, et al. Digitalis must be banished from the table: a rare case of acute accidental Digitalis intoxication of a whole family. J Cardiovasc Med (Hagerstown). 2009;10(9):727-732. (Case report; 3 patients)
  31. Kerns W, 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25(2):309-331. (Review)
  32. * Kline JA, Raymond RM, Schroeder JD, et al. The diabetogenic effects of acute verapamil poisoning. Toxicol Appl Pharmacol. 1997;145(2):357-362. (Animal study; 23 dogs)
  33. Levine M, Boyer EW, Pozner CN, et al. Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007;35(9):2071-2075. (Retrospective review; 5 hospitals, 40 patients)
  34. Pita-Fernandez S, Lombardia-Cortina M, Orozco-Veltran D, et al. Clinical manifestations of elderly patients with digitalis intoxication in the emergency department. Arch Gerontol Geriatr. 2011;53(2):e106-e110. (Retrospective review)
  35. Cooke DM. The use of central nervous system manifestations in the early detection of digitalis toxicity. Heart Lung. 1993;22(6):477-481. (Review)
  36. Kemmerer DA. Devious digoxin: a case review. J Emerg Nurs. 2008;34(5):487-489. (Case report; 1 patient)
  37. Lee TC. Van Gogh’s vision. Digitalis intoxication? JAMA. 1981;245(7):727-729. (Review)
  38. Lely AH, van Enter C. Non-cardiac symptoms of digitalis intoxication. Am Heart J. 1972;83(2):149-152. (Review)
  39. Megarbane B, Deye N, Malissin I, et al. Usefulness of the serum lactate concentration for predicting mortality in acute beta-blocker poisoning. Clin Toxicol (Phila). 2010;48(10):974- 978. (Retrospective study; 110 patients)
  40. Sporer KA, Khayam-Bashi H. Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Am J Emerg Med. 1996;14(5):443-446. (Retrospective chart review; 1820 patients)
  41. Megarbane B, Karyo S, Abidi K, et al. Predictors of mortality in verapamil overdose: usefulness of serum verapamil concentrations. Basic Clin Pharmacol Toxicol. 2011;108(6):385-389. (Chart review; 65 patients)
  42. Varpula T, Rapola J, Sallisalmi M, et al. Treatment of serious calcium channel blocker overdose with levosimendan, a calcium sensitizer. Anesth Analg. 2009;108(3):790-792. (Case report; 2 patients)
  43. Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63(19):1828-1835. (Review)
  44. Olson KR, Erdman AR, Woolf AD, et al. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2005;43(7):797-822. (Clinical practice guideline)
  45. * Levine M, Curry SC, Padilla-Jones A, et al. Critical care management of verapamil and diltiazem overdose with a focus on vasopressors: a 25-year experience at a single center. Ann Emerg Med. 2013;62(3):252-258. (Retrospective chart review; 48 patients)
  46. Eisenberg MJ, Brox A, Bestawros AN. Calcium channel blockers: an update. Am J Med. 2004;116(1):35-43. (Review)
  47. Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med. 1993;22(2):196-200. (Case series, review; 139 patients, 8 receiving atropine)
  48. Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40(6):603-610. (Prospective cohort study; 167 patients)
  49. Rennyson SL, Littmann L. Brugada-pattern electrocardiogram in propranolol intoxication. Am J Emerg Med. 2010;28(2):256 e257-e258. (Case report; 1 patient)
  50. * Ma G, Brady WJ, Pollack M, et al. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med. 2001;20(2):145- 152. (Review)
  51. Sonnenblick M, Abraham AS, Meshulam Z, et al. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed). 1983;286(6371):1089- 1091. (Prospective study; 50 patients)
  52. Raja Rao MP, Panduranga P, Sulaiman K, et al. Digoxin toxicity with normal digoxin and serum potassium levels: beware of magnesium, the hidden malefactor. J Emerg Med. 2013;45(2):e31-e34. (Case report; 1 patient)
  53. Tuncok Y, Hazan E, Oto O, et al. Relationship between high serum digoxin levels and toxicity. Int J Clin Pharmacol Ther. 1997;35(9):366-368. (Retrospective study; 1269 patients)
  54. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871-878. (Post hoc analysis of randomized double-blinded placebo controlled Digitalis Investigation Group (DIG) trial data; 3782 patients)
  55. Ip D, Syed H, Cohen M. Digoxin specific antibody fragments (Digibind) in digoxin toxicity. BMJ. 2009;339:b2884. (Case report and review)
  56. Eyer F, Steimer W, Muller C, et al. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Am J Crit Care. 2010;19(4):391-387. (Case report; 1 patient)
  57. Kirilmaz B, Saygi S, Gungor H, et al. Digoxin intoxication: An old enemy in modern era. J Geriatr Cardiol. 2012;9(3):237- 242. (Retrospective review; 71 patients)
  58. Erickson CP, Olson KR. Case files of the medical toxicology fellowship of the California poison control system-San Francisco: calcium plus digoxin-more taboo than toxic? J Med Toxicol. 2008;4(1):33-39. (Case report; 1 patient)
  59. Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69(18):108G-118G. (Review)
  60. Zand F, Asadi S, Katibeh P. Good outcome after digoxin toxicity despite very high serum potassium level. Iran Red Crescent Med J. 2011;13(9):680-681. (Case report; 1 patient)
  61. Bismuth C, Gaultier M, Conso F, et al. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol. 1973;6(2):153-162. (Prospective study)
  62. Manini AF, Nelson LS, Hoffman RS. Prognostic utility of serum potassium in chronic digoxin toxicity: a case-control study. Am J Cardiovasc Drugs. 2011;11(3):173-178. (Case-control study; 13 fatalities, 13 survivors)
  63. Irons GV, Jr., Orgain ES. Digitalis-induced arrhythmias and their management. Prog Cardiovasc Dis. 1966;8(6):539-569. (Review)
  64. Grimard C, De Labriolle A, Charbonnier B, et al. Bidirectional ventricular tachycardia resulting from digoxin toxicity. J Cardiovasc Electrophysiol. 2005;16(7):807-808. (Case report)
  65. Kaneko Y, Nakajima T, Irie T, et al. Ventricular fibrillation following bidirectional tachycardia due to digitalis toxicity. Intern Med. 2011;50(19):2243. (Case report)
  66. Menduina MJ, Candel JM, Alaminos P, et al. [Bidirectional ventricular tachycardia due to digitalis poisoning]. Rev Esp Cardiol. 2005;58(8):991-993. (Case report)
  67. St-Onge M, Archambault P, Lesage N, et al. Adherence to calcium channel blocker poisoning treatment recommendations in two Canadian cities. Clin Toxicol (Phila). 2012;50(5):424- 430. (Retrospective chart review; 103 patients)
  68. Bond GR. The role of activated charcoal and gastric emptying in gastrointestinal decontamination: a state-of-the-art review. Ann Emerg Med. 2002;39(3):273-286. (Review)
  69. Laine K, Kivisto KT, Laakso I, et al. Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. Br J Clin Pharmacol. 1997;43(1):29-33. (Volunteer study; 32 patients)
  70. No authors listed. Position paper: cathartics. J Toxicol Clin Toxicol. 2004;42(3):243-253. (Position paper)
  71. No authors listed. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol. 2004;42(6):843-854. (Position paper)
  72. Cumpston KL, Aks SE, Sigg T, et al. Whole bowel irrigation and the hemodynamically unstable calcium channel blocker overdose: primum non nocere. J Emerg Med. 2010;38(2):171- 174. (Case report; 2 patients)
  73. Kline JA, Raymond RM, Leonova ED, et al. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34(2):289- 298. (Animal study; 20 dogs)
  74. Agarwal A, Yu SW, Rehman A, et al. Hyperinsulinemia euglycemia therapy for calcium channel blocker overdose: a case report. Tex Heart Inst J. 2012;39(4):575-578. (Case report; 1 patient)
  75. Boyer EW, Shannon M. Treatment of calcium-channelblocker intoxication with insulin infusion. N Engl J Med. 2001;344(22):1721-1722. (Case report)
  76. Engebretsen KM, Kaczmarek KM, Morgan J, et al. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol (Phila). 2011;49(4):277-283. (Review)
  77. Espinoza TR, Bryant SM, Aks SE. Hyperinsulin therapy for calcium channel antagonist poisoning: a seven-year retrospective study. Am J Ther. 2013;20(1):29-31. (Retrospective chart review; 46 patients)
  78. * Greene SL, Gawarammana I, Wood DM, et al. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007;33(11):2019- 2024. (Prospective observational study; 7 patients)
  79. Page C, Hacket LP, Isbister GK. The use of high-dose insulinglucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol. 2009;5(3):139-143. (Case report; 1 patient)
  80. Patel NP, Pugh ME, Goldberg S, et al. Hyperinsulinemic euglycemia therapy for verapamil poisoning: a review. Am J Crit Care. 2007;16(5):498-503. (Review)
  81. Stellpflug SJ, Harris CR, Engebretsen KM, et al. Intentional overdose with cardiac arrest treated with intravenous fat emulsion and high-dose insulin. Clin Toxicol (Phila). 2010;48(3):227-229. (Case report; 1 patient)
  82. * Yuan TH, Kerns WP, 2nd, Tomaszewski CA, et al. Insulinglucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol. 1999;37(4):463- 474. (Case series; 5 patients)
  83. Rosser G, Dubrey SW. Massive calcium channel blocker overdose: intravenous insulin and glucose as a therapy. BMJ Case Rep. Jun 5, 2012. (Case report; 1 patient)
  84. Love JN. Acebutolol overdose resulting in fatalities. J Emerg Med. 2000;18(3):341-344. (Case report; 2 patients)
  85. Pichon N, Dugard A, Clavel M, et al. Extracorporeal albumin dialysis in three cases of acute calcium channel blocker poisoning with life-threatening refractory cardiogenic shock. Ann Emerg Med. 2012;59(6):540-544. (Case series; 3 patients)
  86. Holger JS, Engebretsen KM, Fritzlar SJ, et al. Insulin versus vasopressin and epinephrine to treat beta-blocker toxicity. Clin Toxicol (Phila). 2007;45(4):396-401. (Animal study; 10 pigs)
  87. Albertson TE, Dawson A, de Latorre F, et al. TOX-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med. 2001;37(4 Suppl):S78-S90. (Review)
  88. Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. 1993;22(7):1229-1233. (Case report; 1 patient)
  89. Mahr NC, Valdes A, Lamas G. Use of glucagon for acute intravenous diltiazem toxicity. Am J Cardiol. 1997;79(11):1570- 1571. (Case report; 1 patient)
  90. Rizvi I, Ahmad A, Gupta A, et al. Life-threatening calcium channel blocker overdose and its management. BMJ Case Rep. May 30, 2012. (Case report; 1 patient)
  91. * Bailey B. Glucagon in beta-blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41(5):595-602. (Systematic review; 30 animal studies)
  92. Hoot NR, Benitez JG, Palm KH. Hemodynamically unstable: accidental atenolol toxicity? J Emerg Med. 2013;45(3):355-357. (Case report; 1 patient)
  93. Brubacher JR. Beta-adrenergic antagonists. In: Nelson LS, Lewin NA, Howland MA, et al, eds. Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw-Hill; 2011:896-909.
  94. Wolf LR, Spadafora MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med. 1993;22(7):1225-1228. (Case report; 1 patient)
  95. Kollef MH. Labetalol overdose successfully treated with amrinone and alpha-adrenergic receptor agonists. Chest. 1994;105(2):626-627. (Case report; 1 patient)
  96. Hoeper MM, Boeker KH. Overdose of metoprolol treated with enoximone. N Engl J Med. 1996;335(20):1538. (Case report; 1 patient)
  97. Shanker UR, Webb J, Kotze A. Sodium bicarbonate to treat massive beta blocker overdose. Emerg Med J. 2003;20(4):393. (Case report; 1 patient)
  98. Donovan KD, Gerace RV, Dreyer JF. Acebutolol-induced ventricular tachycardia reversed with sodium bicarbonate. J Toxicol Clin Toxicol. 1999;37(4):481-484. (Case report; 1 patient)
  99. Holstege CP, Furbee Ma, Wermuth ME, et al. Wide complex dysrhythmia in calcium channel blocker overdose responsive to sodium bicarbonate therapy. J Toxicol Clin Toxicol. 1998;36(5):509. (Case report)
  100. Taboulet P, Cariou A, Berdeaux A, et al. Pathophysiology and management of self-poisoning with beta-blockers. J Toxicol Clin Toxicol. 1993;31(4):531-551. (Review)
  101. Holzer M, Sterz F, Schoerkhuber W, et al. Successful resuscitation of a verapamil-intoxicated patient with percutaneous cardiopulmonary bypass. Crit Care Med. 1999;27(12):2818- 2823. (Case report)
  102. Durward A, Guerguerian AM, Lefebvre M, et al. Massive diltiazem overdose treated with extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2003;4(3):372-376. (Case report)
  103. * de Lange DW, Sikma MA, Meulenbelt J. Extracorporeal membrane oxygenation in the treatment of poisoned patients. Clin Toxicol (Phila). 2013;51(5):385-393. (Review)
  104. Rooney M, Massey KL, Jamali F, et al. Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. J Clin Pharmacol. 1996;36(8):760-763. (Case report)
  105. Lane AS, Woodward AC, Goldman MR. Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intra-aortic balloon pump. Ann Emerg Med. 1987;16(12):1381-1383. (Case report)
  106. Frierson J, Bailly D, Shultz T, et al. Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose. Clin Cardiol. 1991;14(11):933-935. (Case report; 1 patient)
  107. Saitz R, Williams BW, Farber HW. Atenolol-induced cardiovascular collapse treated with hemodialysis. Crit Care Med. 1991;19(1):116-118. (Case report; 1 patient)
  108. Ibanez C, Carcas AJ, Frias J, et al. Activated charcoal increases digoxin elimination in patients. Int J Cardiol. 1995;48(1):27- 30. (Chart review; 39 patients)
  109. Critchley JA, Critchley LA. Digoxin toxicity in chronic renal failure: treatment by multiple dose activated charcoal intestinal dialysis. Hum Exp Toxicol. 1997;16(12):733-735. (Case report; 1 patient)
  110. Lapostolle F, Borron SW, Verdier C, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36(11):3014-3018. (Retrospective chart review; 141 patients)
  111. Smith TW, Haber E, Yeatman L, et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294(15):797-800. (Case report; 1 patient)
  112. Antman EM, Wenger TL, Butler VP, Jr., et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81(6):1744-1752. (Retrospective review; 150 patients)
  113. Schaeffer TH, Mlynarchek SL, Stanford CF, et al. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab--a retrospective study. J Am Osteopath Assoc. 2010;110(10):587-592. (Retrospective study; 14 patients)
  114. Ward SB, Sjostrom L, Ujhelyi MR. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind®. Ther Drug Monit. 2000;22(5):599-607. (Randomized trial; 16 patients)
  115. DigiFab® package insert. Protherics. 2005. (Drug package insert)
  116. Digibind® package insert. GlaxoSmithKline. 2003. (Drug package insert)
  117. Eddleston M, Rajapakse S, Rajakanthan, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet. 2000;355(9208):967- 972. (Randomized controlled trial; 66 patients)
  118. Brubacher JR, Lachmanen D, Ravikumar PR, et al. Efficacy of digoxin specific Fab fragments (Digibind®) in the treatment of toad venom poisoning. Toxicon. 1999;37(6):931-942. (Animal study; 45 mice)
  119. Garcia-Rubira JC, Suarez A, Ibanez B. Ventricular fibrillation after correct pacing in digoxin intoxication. J Emerg Med. 2012;42(4):e93-e94. (Case report)
  120. Taboulet P, Baud FJ, Bismuth C, et al. Acute digitalis intoxication--is pacing still appropriate? J Toxicol Clin Toxicol. 1993;31(2):261-273. (Retrospective study; 92 patients)
  121. Santos-Araujo C, Campos M, Gavina C, et al. Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure. Nephrol Dial Transplant. 2007;22(1):257-258. (Case report; 1 patient)
  122. Kinlay S, Buckley NA. Magnesium sulfate in the treatment of ventricular arrhythmias due to digoxin toxicity. J Toxicol Clin Toxicol. 1995;33(1):55-59. (Case report; 1 patient)
  123. Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest. 1997;112(2):556-557. (Case report; 1 patient)
  124. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011;40(1):41-46. (Retrospective chart review; 159 patients)
  125. Bania TC, Chu J, Perez E, et al. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med. 2007;14(2):105-111. (Animal study; 14 dogs)
  126. No authors listed. Bet 2: intralipid/lipid emulsion in betablocker overdose. Emerg Med J. 2011;28(11):991-993. (Review; 8 case reports, 1 case series; 10 patients)
  127. French D, Armenian P, Ruan W, et al. Serum verapamil concentrations before and after Intralipid® therapy during treatment of an overdose. Clin Toxicol (Phila). 2011;49(4):340- 344. (Case report; 1 patient)
  128. * LipidRescue™ Resuscitation...for drug toxicity. 2013; Available at: http://www.lipidrescue.org/. Accessed November 1, 2013. (Website)
  129. Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation. 2009;80(5):591-593. (Case report; 1 patient)
  130. Cave G, Harvey M. Intravenous lipid emulsion as antidote beyond local anesthetic toxicity: a systematic review. Acad Emerg Med. 2009;16(9):815-824. (Systematic review; 14 animal studies, 1 human study, 4 case reports)
  131. ACMT position statement: interim guidance for the use of lipid resuscitation therapy. J Med Toxicol. 2011;7(1):81-82. (Guideline)
  132. Jang DH, Nelson LS, Hoffman RS. Methylene blue in the treatment of refractory shock from an amlodipine overdose. Ann Emerg Med. 2011;58(6):565-567. (Case report; 1 patient)
  133. Aggarwal N, Kupfer Y, Seneviratne C, et al. Methylene blue reverses recalcitrant shock in beta-blocker and calcium channel blocker overdose. BMJ Case Rep. Jan 18, 2013. (Case report; 1 patient)
  134. Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9(3):242-249. (Case report)
  135. St-Onge M, Ajmo I, Poirier D, et al. L-carnitine for the treatment of a calcium channel blocker and metformin poisoning. J Med Toxicol. 2013;9(3):266-269. (Case report)
  136. * Love JN. Beta blocker toxicity after overdose: when do symptoms develop in adults? J Emerg Med. 1994;12(6):799- 802. (Retrospective review; 39 patients)
Publication Information
Authors

Wesley Palatnick, MD, FRCPC; Tomislav Jelic, MD

Publication Date

February 2, 2014

Get Permission

Related Articles

Get Quick-Read Evidence-Based Updates
Enter your email to get free evidence-based content delivered to your inbox once per month.
Please provide a valid email address.